Oncobiologics (NASDAQ:OTLK) Earns “Sell (D-)” Rating from Weiss Ratings

Oncobiologics (NASDAQ:OTLK)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

OTLK has been the topic of a number of other research reports. Chardan Capital reissued a “neutral” rating and set a $3.00 price target on shares of Oncobiologics in a research report on Thursday, August 28th. Ascendiant Capital Markets dropped their price target on Oncobiologics from $21.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Zacks Research downgraded Oncobiologics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 27th. HC Wainwright reissued a “neutral” rating on shares of Oncobiologics in a research report on Tuesday, September 30th. Finally, Guggenheim downgraded Oncobiologics from a “buy” rating to a “neutral” rating in a research report on Thursday, August 28th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

Oncobiologics Stock Up 1.6%

Shares of Oncobiologics stock opened at $1.26 on Friday. The stock’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.63. The company has a market capitalization of $55.97 million, a PE ratio of -2.21 and a beta of 0.56. Oncobiologics has a 52 week low of $0.79 and a 52 week high of $6.98.

Oncobiologics (NASDAQ:OTLK) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.02). The business had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.66 million. As a group, research analysts anticipate that Oncobiologics will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On Oncobiologics

Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its stake in shares of Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares during the last quarter. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

Oncobiologics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.